Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
76.75
+1.25 (1.66%)
At close: Dec 5, 2025, 4:00 PM EST
76.99
+0.24 (0.31%)
After-hours: Dec 5, 2025, 7:44 PM EST
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 99.57, with a low estimate of 70 and a high estimate of 116. The average target predicts an increase of 29.73% from the current stock price of 76.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 3, 2025.
Analyst Ratings
The average analyst rating for Apogee Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 5 | 6 | 5 |
| Buy | 1 | 1 | 2 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 8 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $109 | Strong Buy | Initiates | $109 | +42.02% | Nov 3, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $60 → $70 | Buy | Maintains | $60 → $70 | -8.79% | Nov 3, 2025 |
| Mizuho | Mizuho | Buy Initiates $105 | Buy | Initiates | $105 | +36.81% | Oct 21, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $115 | Strong Buy | Reiterates | $115 | +49.84% | Oct 9, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $60 | Buy | Initiates | $60 | -21.82% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.32
from -3.30
EPS Next Year
-4.92
from -4.32
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.26 | -4.08 | ||||
| Avg | -4.32 | -4.92 | ||||
| Low | -4.33 | -6.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.